

b.) IN THE ABSTRACT

Please amend the abstract at page 60 to read as follows.

Abstract of the Disclosure

~~The present invention relates to a compound~~ E2F-inhibiting compounds are
represented by the general formula (I): R^1-A-R^2 ~~{(I) (wherein R^1 represents substituted or~~
~~unsubstituted alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted~~
~~heteroarylcarbonyl, substituted or unsubstituted alkoxycarbonyl, substituted or~~
~~unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl or a~~
~~hydrogen atom; R^2 represents hydroxy, substituted or unsubstituted alkoxy, or substituted~~
~~or unsubstituted amino; and~~ wherein A represents a peptide sequence comprising a partial
amino acid sequence having at least 12 continuous residues in the sequence of the
dimerization region or DNA binding region of the E2F family); ~~or a pharmaceutically~~
~~acceptable salt thereof, which are useful as a therapeutic agent of diseases such as tumor~~
and arteriosclerosis, for which abnormal cellular growth is responsible.